Composition for promoting bowel movement and use thereof

A lactic acid bacteria fermented powder, comprising specific strains, addresses the side effects of constipation drugs by promoting defecation and enhancing gut health, offering a safe and effective solution for constipation relief.

JP7590587B2Active Publication Date: 2024-11-26GLACT BIOTECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023546382
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-03-31
Filing Date
2022-03-08
Publication Date
2024-11-26
Estimated Expiration
2042-03-08

AI Technical Summary

Technical Problem

Over-the-counter drugs for constipation, such as laxatives and stool softeners, have side effects and are addictive, posing a burden on the body, while lactic acid bacteria are beneficial but insufficient adherence to the intestines complicates intestinal balance and constipation relief.

Method used

A lactic acid bacteria fermented powder composed of strains like Lactobacillus salivarius subsp. salicinius, Lactobacillus plantarum, Lactobacillus acidophilus, and Bifidobacterium longum subsp. infantis, formulated into pharmaceutical or food compositions, promotes defecation and improves constipation without side effects.

Benefits of technology

The lactic acid bacteria fermented powder increases defecation frequency, enhances intestinal comfort, and modifies gut flora to improve constipation symptoms safely and effectively.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590587000004
    Figure 0007590587000004
  • Figure 0007590587000005
    Figure 0007590587000005
  • Figure 0007590587000006
    Figure 0007590587000006
Patent Text Reader

Abstract

The present invention provides a composition for promoting bowel movements and uses thereof. [Solution] The composition for promoting bowel movements of the present invention is a lactic acid bacteria fermented powder consisting of a lactic acid bacteria fermentation product, wherein the lactic acid bacteria fermentation product is obtained by culturing at least a lactic acid bacteria strain in a culture medium containing milk, powdered milk, casein, soybeans, bean products, or whey, and the lactic acid bacteria strain is a lactic acid bacteria fermented powder containing Lactobacillus salivarius subsp. salicinius AP-32 strain, Lactobacillus plantarum LPL28 strain, Lactobacillus acidophilus TYCA06 strain, Bifidobacterium longum subsp. infantis BLI-02 strain, or a combination thereof, and includes a physiologically acceptable excipient, diluent, or carrier.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition, and more particularly to a composition for promoting defecation and use thereof. [Background technology]

[0002] Constipation refers to a condition in which feces are constipated or obstructed, resulting in reduced bowel movements. It is usually caused by a lack of peristaltic function in the large intestine, which delays the passage of feces through the large intestine or the discharge from the rectum. If feces remain in the rectum for too long, the decomposed food will be fermented by bacteria in the large intestine for a long time, producing toxins and harmful gases. If they cannot be discharged on time, the human body will reabsorb these harmful substances, which will enter the bloodstream and cause harm to the human body, leading to various chronic and metabolic diseases. Summary of the Invention [Problem to be solved by the invention]

[0003] However, many of the over-the-counter drugs used to treat constipation, such as common laxatives and stool softeners, cause side effects after taking them, are addictive when taken over a long period of time, and place a significant burden on the body.

[0004] According to a research paper published in The American Journal of Clinical Nutrition in 2014, lactic acid bacteria maintain intestinal balance, improve the time food travels through the intestines, bowel movement frequency, and fecal consistency, and improve constipation when taken over a long period of time. However, lactic acid bacteria are defined as active bacteria that are beneficial to the human body, and if the amount of lactic acid bacteria that adhere or colonize the intestines is insufficient, it becomes difficult to maintain intestinal balance and improve constipation.

[0005] As described above, there is a strong need to develop a supplement that can be safely taken for a long time and has a defecation promoting effect. Therefore, since lactobacillus fermentation products are safer than many commercially available drugs for treating constipation, have no burden on the human body, and are rapidly absorbed by the human body, they have a defecation promoting effect, so that the pursuit of lactobacillus fermentation products that can be used to prepare compositions that improve constipation has become one of the most urgent goals in the technical field to which the present invention belongs.

[0006] Therefore, the present inventors believed that the above-mentioned drawbacks could be improved, and as a result of extensive research, they came to propose the present invention, which effectively improves the above-mentioned problems through rational design.

[0007] In view of the above-mentioned conventional situation, the present invention aims to provide a lactobacillus-fermented powder that promotes bowel movements, i.e., promotes bowel movements frequency and improves constipation in different forms such as a food composition or a pharmaceutical composition. [Means for solving the problem]

[0008] According to one embodiment of the present invention, there is provided a composition for promoting defecation, which is a lactic acid bacteria fermentation powder comprising a lactic acid bacteria fermentation product, the lactic acid bacteria fermentation product being obtained by culturing at least a lactic acid bacteria strain in a medium containing milk, milk powder, casein, soybean, a bean product, or whey, the lactic acid bacteria strain being Lactobacillus salivarius subsp. salicinius AP-32 strain, Lactobacillus plantarum LPL28 strain, Lactobacillus acidophilus TYCA06 strain, Bifidobacterium longum subsp. infantis BLI-02 strain, or a combination thereof, and a physiologically acceptable excipient, diluent, or carrier. The Lactobacillus salivarius subsp. salicinius AP-32 strain has been deposited in the China Center for Typical Culture Preservation under the accession number CCTCC M2011127, the Lactobacillus plantarum LPL28 strain has been deposited in the China Center for Common Microorganism Preservation under the accession number CGMCC 17954, the Lactobacillus acidophilus TYCA06 strain has been deposited in the China Center for Common Microorganism Preservation under the accession number CGMCC 15210, and the Bifidobacterium longum subsp. infantis BLI-02 strain has been deposited in the China Center for Common Microorganism Preservation under the accession number CGMCC 15212.

[0009] In a preferred embodiment of the present invention, the lactic acid bacteria strains include Lactobacillus salivarius subsp. salicinius AP-32 strain, Lactobacillus plantarum LPL28 strain, Lactobacillus acidophilus TYCA06 strain, and Bifidobacterium longum subsp. infantis BLI-02 strain.

[0010] In a preferred embodiment of the present invention, the composition is a pharmaceutical composition or a food composition, but is not limited thereto.

[0011] In one preferred embodiment of the present invention, when the composition is a pharmaceutical composition, the physiologically acceptable excipient, diluent, or carrier includes, but is not limited to, a medicamentable excipient, diluent, or carrier.

[0012] In one preferred embodiment of the invention, the pharmaceutical composition is in the form of, but not limited to, a tablet, capsule, powder, emulsion, spray, gel, solution, dispersion, or ointment.

[0013] In one preferred embodiment of the present invention, when the composition is a food composition, the physiologically acceptable excipient, diluent, or carrier is, but is not limited to, an edible excipient, diluent, or carrier.

[0014] In one preferred embodiment of the present invention, the food composition is, but is not limited to, fermented milk, yogurt, cheese, milk drink or milk powder, tea, coffee, functional beverage, or combinations thereof.

[0015] In a preferred embodiment of the present invention, the lactic acid bacteria fermentation product accounts for 2 to 40% by weight, based on the total weight of the composition.

[0016] In a preferred embodiment of the present invention, the lactic acid bacteria fermentation product is, but is not limited to, a fermentation supernatant of a culture medium, a fermentation supernatant containing an inactivated strain of a culture medium, a fermentation supernatant of a culture medium from which the bacterial cells have been removed, or a dried powder thereof.

[0017] In a preferred embodiment of the invention, the composition further comprises a prebiotic.

[0018] In view of the effect of the above-mentioned composition in promoting defecation in the human or animal body, the present invention further provides the use of the above-mentioned composition in the preparation of a composition for relieving constipation.

[0019] In a preferred embodiment of the present invention, symptoms of constipation include fecal retention, reduced fecal volume, impaired defecation, insufficient defecation, or reduced frequency of defecation.

[0020] Other features of the present invention will become apparent from the following detailed description of the present invention and the accompanying drawings. [Brief description of the drawings]

[0021] [Figure 1] 1 is a graph showing the statistics of defecation frequency for subjects in different groups. [Diagram 2] 1 is a bar graph showing subjective gastrointestinal health comfort perception after taking different types or doses of capsules. [Diagram 3] 1 is a graph showing the degree of change in the microbiota of subjects from different groups. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0022] Hereinafter, embodiments of the composition for promoting bowel movement of the present invention will be described with reference to the drawings. However, the present invention is not limited to these embodiments, and the components, materials, etc. described below can be modified in various ways within the spirit and scope of the present invention.

[0023] The freeze-dried cultures of the above lactic acid bacteria strains of the present invention have been deposited at the China Typical Culture Preservation Center, Wuhan University, Wuhan, China, or at the China Common Microorganism Species Preservation and Management Center, No. 3, Hall No. 1, Beichen West Road, Chaoyang District, Beijing, China. The details of the deposits are shown in Table 1 below.

[0024] JPEG0007590587000001.jpg106170

[0025] The present inventors have found that the fermented product of the strains listed in Table 1 above has the effect of increasing the frequency of bowel movements, and therefore, the fermented product is used as a composition to produce a powder to alleviate constipation.

[0026] A composition for promoting defecation according to one embodiment of the present invention is a lactic acid bacteria fermentation powder comprising a lactic acid bacteria fermentation product, the lactic acid bacteria fermentation product being obtained by culturing at least a lactic acid bacteria strain in a medium containing milk, milk powder, casein, soybean, bean products, or whey, the lactic acid bacteria strain being selected from the group consisting of Lactobacillus salivarius subsp. salicinius AP-32 strain deposited at the China Center for Typical Culture Preservation under accession number CCTCC M2011127, Lactobacillus plantarum LPL28 strain deposited at the China Center for Common Microorganism Preservation under accession number CGMCC 17954, Lactobacillus acidophilus LPL28 strain deposited at the China Center for Common Microorganism Preservation under accession number CGMCC 15210, Lactobacillus salivarius subsp. salicinius AP-32 strain deposited at the China Center for Common Microorganism Preservation under accession number CGMCC 17954, Lactobacillus acidophilus LPL28 strain deposited at the China Center for Common Microorganism Preservation under accession number CGMCC 15210, Lactobacillus salivarius subsp. salicinius AP-32 strain deposited at the China Center for Typical ... The composition includes a lactic acid bacteria fermentation powder containing a Bifidobacterium longum subsp. infantis BLI-02 strain deposited in the China Center for General Microorganism Species Preservation Management under the accession number CGMCC 15212, or a combination thereof, and a physiologically acceptable excipient, diluent, or carrier. In one preferred embodiment, the lactic acid bacteria fermentation product accounts for 2 to 40% by weight based on the total weight of the composition. In another preferred embodiment, the lactic acid bacteria fermentation product is a fermentation supernatant of a medium, a fermentation supernatant containing an inactivated strain of a medium, a fermentation supernatant of a medium from which the cells of the medium have been removed, or a dried powder thereof. In yet another preferred embodiment, the lactic acid bacteria strain includes at least the above-mentioned four types of strains.

[0027] In addition, in order to meet the actual demand, the composition according to the present embodiment is in the form of a pharmaceutical composition or a food composition. In the form of a pharmaceutical composition, the physiologically acceptable excipient, diluent, or carrier is a medicinal excipient, diluent, or carrier, and the pharmaceutical composition is in the form of a tablet, capsule, powder, emulsion, spray, gel, solution, dispersion, or ointment. In the form of a food composition, the physiologically acceptable excipient, diluent, or carrier is an edible excipient, diluent, or carrier, and the food composition is fermented milk, yogurt, cheese, milk drink or milk powder, tea, coffee, or functional drink. In addition, the composition according to the present embodiment further contains prebiotics to promote the growth of good bacteria in the gastrointestinal tract. The addition of prebiotics can enhance the gastrointestinal function and enhance the defecation effect of the composition according to the present embodiment.

[0028] Based on the function of the composition according to the above-mentioned embodiment, another embodiment of the present invention provides a use of the above-mentioned composition for the preparation of a composition for improving constipation, the symptoms of which include at least stool retention, reduced stool volume, impaired defecation, insufficient defecation, or reduced frequency of defecation.

[0029] Example 1: Morphology and general properties of lactic acid bacteria strains The taxonomic characteristics of the strain were confirmed by 16s rRNA sequence analysis and API bacterial identification system. The morphological and general characteristics of the strain in this example are shown in Table 2 below.

[0030] JPEG0007590587000002.jpg211170

[0031] <Example 2: Preparation of lactic acid bacteria fermented powder> The lactic acid bacteria fermented powder according to this embodiment is produced by first culturing and fermenting a combination of the above-mentioned isolated Lactobacillus salivarius subsp. salicinius AP-32 strain, Lactobacillus plantarum LPL28 strain, Lactobacillus acidophilus TYCA06 strain, and Bifidobacterium longum subsp. infantis BLI-02 strain in a medium containing milk, powdered milk, casein, soybeans, bean products, or whey. Next, the medium is centrifuged to obtain a fermentation liquid, and the strains in the fermentation liquid are inactivated by heat sterilization, and the bacteria in the fermentation liquid are removed, or the fermentation liquid is dried to form a dry powder. The dried powder is the lactic acid bacteria fermented powder according to this embodiment. The fermentation liquid in which the strains are inactivated or the fermentation liquid from which the bacteria are removed is treated to form the lactic acid bacteria fermented powder according to this embodiment.

[0032] <Example 3: Defecation test of lactic acid bacteria fermented powder> In this example, the defecation promoting effect of the lactobacillus fermented powder according to the above example in the human body is tested. First, 200 mg of lactobacillus fermented powder and maltodextrin are mixed to prepare a capsule, and the capsule content is 500 mg. A capsule is prepared with 500 mg of maltodextrin as a control group. Next, 45 subjects are divided into three groups, 15 subjects in each group, and the number of bowel movements per week before the test is recorded for each subject. Then, one of the groups takes the control capsule containing only maltodextrin every day, the other group takes one capsule containing 200 mg of lactobacillus fermented powder every day, and the other group takes three capsules containing 200 mg of lactobacillus fermented powder every day. The period is one month, and the number of bowel movements in the final week of each subject's intake is recorded.

[0033] As shown in Figure 1, the number of bowel movements of the subjects who took the control capsule did not increase, indicating that maltodextrin does not promote bowel movements. The number of bowel movements of the subjects who took 200 mg of lactobacillus fermented powder every day increased slightly, but not significantly. The number of bowel movements of the subjects who took 600 mg of lactobacillus fermented powder every day increased significantly. In summary, this example proves that lactobacillus fermented powder increases bowel movement frequency.

[0034] <Example 4: Lactic acid bacteria fermentation powder intestinal and stomach health experience test> In this embodiment, the effect of the lactic acid bacteria fermented powder according to the above embodiment on the intestinal and stomach health of the human body is tested. First, 200 mg of lactic acid bacteria fermented powder and maltodextrin are mixed to prepare a capsule, and the capsule content is 500 mg. A capsule is prepared with 500 mg of maltodextrin as a control group. Next, 15 subjects are divided into three groups, each group has 5 subjects. Then, each group takes the capsule of the control group, one capsule containing 200 mg of lactic acid bacteria fermented powder, and three capsules containing 200 mg of lactic acid bacteria fermented powder in a random order for a certain period of time. The interval between taking the last capsule and taking the next capsule is 1 week, and the bodily experience scores such as improvement of constipation, improvement of flatulence, improvement of diarrhea, improvement of upper abdominal pain, and improvement of lower abdominal pain are recorded during the period of taking each capsule.

[0035] Next, as shown in Figure 2, after taking the control capsule, the subject did not feel any improvement in intestinal and stomach comfort. After taking 200mg of lactic acid bacteria fermented powder every day, the subject felt a slight improvement in intestinal and stomach comfort, but it was not significant. After taking 600mg of lactic acid bacteria fermented powder every day, the subject felt a clear improvement in intestinal and stomach comfort. In summary, this example proves that lactic acid bacteria fermented powder can improve the physical comfort of intestinal and stomach health.

[0036] <Example 5: Gastrointestinal bacterial flora test of lactic acid bacteria fermented powder> In this embodiment, the effect of the lactobacillus fermented powder according to the above embodiment on the human gastrointestinal flora is tested. First, 200 mg of lactobacillus fermented powder and maltodextrin are mixed to prepare capsules, and the capsule contents are 500 mg. A capsule is prepared with 500 mg of maltodextrin as a control group. Then, 45 subjects are divided into three groups, with 15 subjects in each group, and fecal samples are collected from each subject before the test. Then, one group takes the control capsule containing only maltodextrin every day, the other group takes one capsule containing 200 mg of lactobacillus fermented powder every day, and the other group takes three capsules containing 200 mg of lactobacillus fermented powder every day. The period is one month, and fecal samples are collected from each subject after the test. Finally, the bacterial flora of the fecal samples is examined using next generation sequencing (NGS).

[0037] Bifidobacterium, Akkermansia, Lactococcus, and Lactobacillus belong to good bacteria, while Enterococcus and Streptococcus belong to pathogenic bacteria. As shown in FIG. 3, the subjects who took the control capsule showed a slight increase in pathogenic flora and a slight decrease in good flora. The subjects who took 200 mg of lactic acid bacteria fermented powder every day showed a slight increase in both pathogenic flora and good flora. The subjects who took 600 mg of lactic acid bacteria fermented powder every day showed a significant decrease in pathogenic flora and a significant increase in good flora.

[0038] <Example 6: Fecal moisture content test of lactic acid bacteria fermented powder> In this example, the effect of the lactobacillus fermentation powder according to the above-mentioned example on the water content of feces in constipated mice is tested. First, 7-8 week old Balb / c mice are fed or injected with the antidiarrheal drug loperamide hydrochloride to establish an animal model of constipated mice. Then, the mice are divided into a control group, a Lactobacillus salivarius subsp. salicinius AP-32 strain fermentation group, a Lactobacillus plantarum LPL28 strain fermentation group, a Lactobacillus acidophilus TYCA06 strain fermentation group, a Bifidobacterium longum subsp. infantis BLI-02 strain fermentation group, a 4-stranded strain fermentation group, and a 4-stranded strain active group. The term "quadruple strain" refers to the combination of the above-mentioned Lactobacillus salivarius subsp. salicinius AP-32 strain, Lactobacillus plantarum LPL28 strain, Lactobacillus acidophilus TYCA06 strain, and Bifidobacterium longum subsp. infantis BLI-02 strain. Then, 0.25 mL of saline solution is used as the solvent, and the mice are fed twice a day for a total of 8 days. The "control group" is fed only saline every time. The "Lactobacillus salivarius subsp. salicinius AP-32 strain fermentation group", "Lactobacillus plantarum LPL28 strain fermentation group", "Lactobacillus acidophilus TYCA06 strain fermentation group", and "Bifidobacterium longum subsp. infantis BLI-02 strain fermentation group" are fed 600 mg of the corresponding one kind of lactobacillus strain fermentation every time. The "four-strain fermentation group" was fed 600 mg of four-strain fermentation product (150 mg of each lactic acid bacteria strain fermentation product) each time. The "four-strain active bacteria group" was fed 2 x 10 10 cfu4 Streptococcus elegans strain active bacteria (various lactic acid bacteria strain active bacteria 5x10 9 cfu) were fed to the mice. Then, the feces of the mice were collected and the moisture content was calculated. The formula for the moisture content of feces is as follows:

[0039] Fecal moisture content (%) = (wet weight of feces - dry weight of feces) / wet weight of feces × 100%

[0040] The results of the fecal water content analysis are shown in Table 3.

[0041] JPEG0007590587000003.jpg83170

[0042] As can be seen from the above table, the increased fecal moisture content (0.3%) of the fermented product of the 4-strain group is higher than the average value (0.2%) of the fermented product of Lactobacillus salivarius subsp. salicinius AP-32 strain, the fermented product of Lactobacillus plantarum LPL28 strain, the fermented product of Lactobacillus acidophilus TYCA06 strain, and the fermented product of Bifidobacterium longum subsp. infantis BLI-02 strain. This indicates that the fermented product of the 4-strain group has a synergistic effect on the increase in fecal moisture content. In summary, this example proves that the lactic acid bacteria fermentation powder obtained in Example 1 has caused an unexpected increase in fecal moisture content.

[0043] It should be noted that lactic acid bacteria fermentation powder is a mixture of lactic acid bacteria metabolic products, and its function on human health is due to the specificity of the composition nutrients, not only the lactic acid bacteria active bacteria themselves, and metabolic products that have special effects on human health are called "postbiotics" (see Trends in Food Science & Technology. 2018-05, 75:105-114). In addition, the human body's response to postbiotics is determined by the strain of bacteria, complete culture, processing process, and complete clinical report. For example, according to an article published in the International Journal of Molecular Sciences Vol.20 No.19 in 2019, the material states that the currently known processing methods of postbiotics include heat sealing, physical processing, high water pressure processing, freeze drying, or ultrasonic vibration, and the health promotion effect cannot be achieved by carrying out the processing appropriately.

[0044] The present invention can be implemented in various other forms without departing from its spirit or main features. Therefore, the above-described embodiments are merely illustrative in all respects and should not be interpreted as being limiting. The scope of the present invention is defined by the claims and is not limited to the text of the specification. Furthermore, all modifications and changes within the scope of the claims are within the scope of the present invention.

Claims

1. A lactic acid bacteria fermented powder comprising a lactic acid bacteria fermentation product, The lactic acid bacteria fermentation product is obtained by culturing at least a lactic acid bacteria strain in a medium containing milk, powdered milk, casein, soybeans, bean products, or whey, and the lactic acid bacteria strain is Lactobacillus salivarius subsp. salicinius AP-32 strain, Lactobacillus plantarum LPL28 strain, Lactobacillus acidophilus TYCA06 strain, Bifidobacterium longum subsp. infantis BLI-02 strain, or a combination thereof; The Lactobacillus salivarius subsp. salicinius AP-32 strain was deposited in the China Center for Typical Culture Collection under the accession number CCTCC M2011127; The Lactobacillus plantarum LPL28 strain was deposited at the China General Microorganism Species Preservation Center under the accession number CGMCC 17954. The Lactobacillus acidophilus TYCA06 strain has been deposited at the China General Microorganism Species Preservation Center under the accession number CGMCC 15210; The Bifidobacterium longum subsp. infantis BLI-02 strain is a lactic acid bacteria fermentation powder deposited in the China General Microorganism Species Preservation Management Center under the accession number CGMCC 15212; a physiologically acceptable excipient, diluent, or carrier; A composition for promoting defecation, characterized in that the lactic acid bacteria strains include Lactobacillus salivarius subsp. salicinius AP-32 strain, Lactobacillus plantarum LPL28 strain, Lactobacillus acidophilus TYCA06 strain, and Bifidobacterium longum subsp. infantis BLI-02 strain.

2. A composition for promoting defecation according to claim 1, characterized in that the composition is a pharmaceutical composition or a food composition.

3. The composition for promoting defecation according to claim 2, characterized in that when the composition is a food composition, the physiologically acceptable excipient, diluent or carrier is an edible excipient, diluent or carrier, and the food composition is fermented milk, yogurt, cheese, a milk drink or milk powder, tea, coffee, a functional drink, or a combination thereof.

4. The composition for promoting defecation according to claim 2, characterized in that when the composition is a pharmaceutical composition, the physiologically acceptable excipient, diluent, or carrier is a medicamentable excipient, diluent, or carrier, and the pharmaceutical composition is in the form of a tablet, capsule, powder, emulsion, spray, gel, solution, dispersion, or ointment.

5. 2. The composition for promoting defecation according to claim 1, characterized in that the lactic acid bacteria fermentation product accounts for 2 to 40% by weight, based on the total weight of the composition.

6. 2. The composition for promoting defecation according to claim 1, wherein the lactic acid bacteria fermentation product is a fermentation supernatant of a culture medium, a fermentation supernatant containing an inactivated strain of a culture medium, a fermentation supernatant of a culture medium from which the bacterial cells have been removed, or a dried powder thereof.

7. 2. The composition for promoting bowel movement according to claim 1, further comprising a prebiotic.

8. Use of the composition according to any one of claims 1 to 7, characterized in that it is used in the preparation of a composition for relieving constipation.

9. 9. The use of the composition according to claim 8, wherein the symptoms of constipation include fecal constipation, reduced fecal volume, impaired defecation, insufficient defecation, or reduced frequency of defecation.

Citation Information

Patent Citations

  • Special female probiotic composition and application thereof

    CN111150059A

  • Vaginitis pathogen-inhibiting composition, vagina-cleaning composition, and uses thereof

    US20210121508A1

  • Composition for promoting defecation and uses thereof

    US20210401906A1

  • Probiotic compositions and uses thereof

    WO2007140621A1